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Letter to the Editor 
Serum LDH, a prognostic
factor in elderly patients
with acute myelogenous
leukaemia 
Sir, 
We read with interest the recent letter correlating pre-induction
serum LDH to clinical outcome in patients with germ cell tumours
by Shamash et al (2000), and would like to confirm the findings 
of Ånström and co-workers (2000) with regard to serum LDH 
and clinical outcome in older patients with acute myelogenous
leukaemia (AML). 
Between July 1987 and December 1999 124 consecutive patients
with newly diagnosed AML (age > 60 years) were managed at 
St Bartholomew’s Hospital. 75 patients were selected for treat-
ment with curative intent on clinical grounds, and received mito-
xantrone in combination with cytarabine (mitoxantrone 12 mg/m2
i.v. for 3 days; n = 49, 10 mg/m2 i.v. for 5 days; n = 26, cytarabine
100 mg/m2 bd i.v. 7 days). The remaining patients received
supportive care with blood products and antibiotic therapy as
appropriate. 
Complete remission (CR) was achieved in 34/75 patients (45%)
(27% of the entire cohort). The only factor predictive of CR on
multivariate analysis was age. With a median follow up of 5.5
years, for patients treated with curative intent, actuarial survival at
1, 3 and 5 years was 33%, 10% and 7% respectively. By univariate
analysis, serum LDH, cytogenetic subgroup and patient age correl-
ated with overall survival. ‘Unfavourable’ karyotype and raised
LDH (>twice upper limit of normal) were found to be the factors
most highly predictive for poor overall survival by multivariate
analysis (Table 1). 
The clinical outcome for older patients with AML is frequently
disappointing. Many of those treated with curative intent experi-
ence significant morbidity, in addition, 30% die as a result of
complications associated with induction therapy, and the CR rate
is often no better than 40–50% (Hiddemann et al, 1999). Thus the
decision to offer treatment with curative intent to the older person
with AML is not straightforward. 
Serum LDH is an important prognostic factor, predicting for
clinical outcome in both haematological and non-haematological
malignancy. By utilizing this simple laboratory test, alone or in
combination with other prognostic factors, it may be possible to
select older patients who are likely to benefit from curative
therapy (Ferrara and Mirto, 1996). 
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Table 1 Prognostic factors for overall survival in newly diagnosed elderly
patients treated with mitoxantrone and cytarabine 
Multivariate analysis HR 95% confidence  P value
interval 
Serum LDH* 3.29 1.38–7.86 P = 0.01 
(>twice upper limit of normal) 
Age/(5 year increment) 1.84 1.15–2.95 P = 0.01 
Cytogenetic sub-groupa
(base line: Normal) 
‘Unfavourable’ 4.24 1.42–12.6 P = 0.01
HR>1 indicates poor overall survival. Serum LDH*: normal range (240–
480 IU/l). Cytogenetic sub-groupa: ‘Unfavourable’ sub-group [-5/5q-, -7,
Complex karyotype (3 or more distinct chromosomal rearrangements)]. 
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